AAMU
RPRX icon

Amundi Asset Management US’s Royalty Pharma RPRX Stock Holding History

Amundi Asset Management US’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$121M Buy
2,779,611
+831,887
+43% +$39.4M 0.09% 232
2020
Q4 		$97.5M Buy
+1,947,724
New +$82.6M 0.08% 262

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
SGA
Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Amundi Asset Management US's RPRX Position: Q1 2021 in Review

Amundi Asset Management US increased its Royalty Pharma (RPRX) stake by 43% in Q1 2021, buying an estimated $39.4M and bringing the position to 2,779,611 shares worth $121M. The position accounts for 0.09% of the portfolio, ranked #232.

Amundi Asset Management US first reported a position in RPRX in Q4 2020 and has held it in 2 quarters since. 214 funds tracked by Wall St. Rank hold RPRX as of Q1 2021.

  • Amundi Asset Management US held 2,779,611 shares of Royalty Pharma worth $121M as of Q1 2021.
  • Amundi Asset Management US bought 831,887 Royalty Pharma shares in Q1 2021, an estimated $39.4M.
  • Royalty Pharma made up 0.09% of Amundi Asset Management US's portfolio in Q1 2021, its #232 holding.
  • Amundi Asset Management US first reported a position in Royalty Pharma in Q4 2020 and has held it in 2 quarters since.
  • 214 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.